Korean J Schizophr Res Search

CLOSE


Korean J Schizophr Res > Volume 15(2); 2012 > Article
Korean Journal of Schizophrenia Research 2012;15(2):99-105.
DOI: https://doi.org/10.16946/kjsr.2012.15.2.99    Published online October 31, 2012.
Psychomotor Performance Relevant to Driving Ability in Patients with Schizophrenia Treated with Haloperidol and Aripiprazole.
Ji Hyun Han, Se Jin Park, Jong Il Lee, An Kee Chang, Shi Hyun Kang, Minah Soh, Kyung Jin Lee, Eun Sang Koh, Sungwon Roh
1Department of Psychiatry, Seoul National Hospital, Seoul, Korea.
2Department of Mental Health Research, Seoul National Hospital, Seoul, Korea. swroh@korea.kr
3Ansan Yoon Neuropsychiatric Clinic, Ansan, Korea.
4Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVES
This study aimed to compare psychomotor performance related with automobile driving in patients with schizophrenia under the treatment of a typical antipsychotic agent, haloperidol, or an atypical antipsychotic agent, aripiprazole.
METHODS
We evaluated driving ability of schizophrenia patients by using the cognitive perceptual assessment for driving (CPAD). Twelve patients receiving haloperidol monotherapy and 18 taking aripiprazole monotherapy participated in this study and the results of CPAD were compared with each other.
RESULTS
Of 30 participants, 15 (50%) of the patients passed the CPAD to be regarded as competent to drive, 3 (10%) of the patients failed the CPAD considered to be severely impaired. Controlling for sex, age, education, duration of illness, there were no significant differences in the CPAD results between two treatment groups. We observed a trend that patients who received aripiprazole showed a higher total score of the CPAD than haloperidol-treated patients (55.2+/-4.9 vs. 45.7+/-8.4, p=0.080).
CONCLUSION
There were no significant differences in the psychomotor performance relevant to driving ability between haloperidol and aripiprazole groups. But our results suggest that aripiprazole might have the neurocognitive advantage over haloperidol. Future study with a large sample size and diverse antipsychotics is warranted.
Key Words: Schizophrenia · Haloperidol · Aripiprazole · Driving · Psychomotor performance


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
15 Teheran-ro 82-gil, Gangnam-gu, Seoul 06178, Korea
Tel: +82-2-552-6677    Fax: +82-31-554-2599    E-mail: thanato96@naver.com                

Copyright © 2022 by Korean Society for Schizophrenia Research.

Developed in M2PI

Close layer
prev next